哮喘吸入缓解治疗:系统综述与Meta分析
该系统综述与Meta分析纳入27项随机临床试验共50496例成人和儿童哮喘患者,比较单用短效β激动剂(SABA)与含吸入性糖皮质激素(ICS)的缓解治疗方案。与单用SABA相比,ICS-福莫特罗和ICS-SABA均与重度急性发作减少和哮喘控制改善相关,证据确定性高;间接比较中ICS-福莫特罗较ICS-SABA重度急性发作更少,证据确定性中等。
要点
- 与单用SABA相比,ICS-福莫特罗(RR 0.65)和ICS-SABA(RR 0.84)均与重度急性发作减少相关,证据确定性高。
- 与单用SABA相比,两种含ICS缓解方案均与哮喘控制改善相关,证据确定性高。
- 间接比较中,ICS-福莫特罗较ICS-SABA与重度急性发作更少相关(RR 0.78),证据确定性中等。
核心结论
- 在哮喘患者中,与单用SABA相比,ICS联合福莫特罗和ICS联合SABA均与哮喘急性发作减少和哮喘控制改善相关。
研究设计与样本
- 系统综述与随机效应Meta分析,检索MEDLINE、Embase和CENTRAL数据库2020年1月1日至2024年9月27日,无语言限制。
- 纳入27项随机临床试验,共50496例成人和儿童哮喘患者,平均年龄41.0岁,男性20288例(40%)。
- 由两名评价者独立筛选研究、提取数据并评估偏倚风险,采用GRADE评估证据确定性。
主要发现
- 与单用SABA相比,ICS-福莫特罗与重度急性发作减少相关(RR 0.65,95%CI 0.60-0.72;RD -10.3%,95%CI -11.8%至-8.3%),证据确定性高。
- 与单用SABA相比,ICS-SABA与重度急性发作减少相关(RR 0.84,95%CI 0.73-0.95;RD -4.7%,95%CI -8.0%至-1.5%),证据确定性高。
- 与单用SABA相比,ICS-福莫特罗与哮喘控制改善相关(总分达到最小重要差异的RR 1.07,95%CI 1.04-1.10;RD 4.1%,95%CI 2.3%-5.9%),证据确定性高。
- 与单用SABA相比,ICS-SABA与哮喘控制改善相关(RR 1.09,95%CI 1.03-1.15;RD 5.4%,95%CI 1.8%-8.5%),证据确定性高。
- 间接比较中,ICS-福莫特罗较ICS-SABA与重度急性发作更少相关(RR 0.78,95%CI 0.66-0.92;RD -5.5%,95%CI -8.4%至-2.0%),证据确定性中等。
关键数值与推荐
- 与单用SABA相比,ICS-福莫特罗未增加严重不良事件风险(RD -0.6%,95%CI -1.3%至0%),证据确定性高。
- 与单用SABA相比,ICS-SABA未增加严重不良事件风险(RD 0%,95%CI -1.1%至1.2%),证据确定性中等。
- 哮喘控制问卷5条目版评分范围0-6分,评分越低控制越好,最小重要差异为0.5分。
- 哮喘生活质量问卷评分范围1-7分,评分越高生活质量越好,最小重要差异为0.5分。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: The optimal inhaled reliever therapy for asthma remains unclear. OBJECTIVE: To compare short-acting β agonists (SABA) alone with SABA combined with inhaled corticosteroids (ICS) and with the fast-onset, long-acting β agonist formoterol combined with ICS for asthma. DATA SOURCES: The MEDLINE, Embase, and CENTRAL databases were searched from January 1, 2020, to September 27, 2024, without language restrictions. STUDY SELECTION: Pairs of reviewers independently selected randomized clinical trials evaluating (1) SABA alone, (2) ICS with formoterol, and (3) ICS with SABA (combined or separate inhalers). DATA EXTRACTION AND SYNTHESIS: Two reviewers independently extracted data and assessed risk of bias. Random-effects meta-analyses synthesized outcomes. GRADE (Grading of Recommendations Assessment, Development, and Evaluation) was used to evaluate the certainty of evidence. MAIN OUTCOMES AND MEASURES: Asthma symptom control (5-item Asthma Control Questionnaire; range, 0-6, lower scores indicate better asthma control; minimum important difference [MID], 0.5 points), asthma-related quality of life (Asthma Quality of Life Questionnaire; range, 1-7, higher scores indicate better quality of life; MID, 0.5 points), risk of severe exacerbations, and risk of serious adverse events. RESULTS: A total of 27 randomized clinical trials (N = 50 496 adult and pediatric patients; mean age, 41.0 years; 20 288 male [40%]) were included. Compared with SABA alone, both ICS-containing relievers were associated with fewer severe exacerbations (ICS-formoterol risk ratio [RR], 0.65 [95% CI, 0.60-0.72]; risk difference [RD], -10.3% [95% CI, -11.8% to -8.3%]; ICS-SABA RR, 0.84 [95% CI, 0.73-0.95]; RD, -4.7% [95% CI, -8.0% to -1.5%]) with high certainty. Compared with SABA alone, both ICS-containing relievers were associated with improved asthma control (ICS-formoterol RR improvement [MID] in total score, 1.07 [95% CI, 1.04-1.10]; RD, 4.1% [95% CI, 2.3%-5.9%]; ICS-SABA RR, 1.09 [95% CI, 1.03-1.15]; RD, 5.4% [95% CI, 1.8%-8.5%]) with high certainty. In an indirect comparison with ICS-SABA, ICS-formoterol was associated with fewer severe exacerbations (RR, 0.78 [95% CI, 0.66-0.92]; RD, -5.5% [95% CI, -8.4% to -2.0%]) with moderate certainty. Compared with SABA alone, ICS-formoterol (RD, -0.6% [95% CI, -1.3% to 0%]) was not associated with increased risk of serious adverse events (high certainty) and ICS-SABA (RD, 0% [95% CI, -1.1% to 1.2%]) was not associated with increased risk of serious adverse events (moderate certainty). CONCLUSIONS AND RELEVANCE: In this network meta-analysis of patients with asthma, ICS combined with formoterol and ICS combined with SABA were each associated with reduced asthma exacerbations and improved asthma control compared with SABA alone.
引用
- Rayner DG, Ferri DM, Guyatt GH, et al. Inhaled Reliever Therapies for Asthma: A Systematic Review and Meta-Analysis. JAMA. 2025. PMID: 39465893. doi:10.1001/jama.2024.22700
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。